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ABSTRACT OF THESIS 
 
Nanomaterials and Block Copolymers for Overcoming Multidrug Resistance in Cancer 
 
by 
 
Wesley Livingston 
 
Master of Science, Graduate Program in Biochemistry 
Loma Linda University, June 2011 
Dr. Christopher Perry, Chairperson 
 
 
The development of multidrug resistance in cancer is one of the leading 
causes for decreased chemotherapy efficacy and is particularly threatening to 
aggressive cancers such as that of the pancreas. In cancers where chemotherapy is 
amongst the few treatment options, it is crucial to develop chemotherapeutics that 
either bypass or control the development of multidrug resistance. Polymeric 
nanomaterials such as Pluronics® are of current interest due to their ability to 
perform these functions in addition to enhancing pro-apoptotic mechanisms. 
Using the respectively known chemosensitive and chemoresistant pancreatic 
adenocarcinoma cell lines MiaPaCa-2 and PANC-1, an in vitro analysis of the 
synergistic effect using 5-fluorouracil in conjugation with Pluronic® F127 was 
performed. By monitoring cell viability and regulation of cell cycle, we were able 
to show that compared to the use of 5-flurouracil alone, there was enhanced 
cytotoxicity when using drug associated with Pluronic® F127 in MiaPaCa-2 cells. 
The more chemoresistant cell line PANC-1 showed no significant enhancement of 
5-fluorouracil cytotoxicity when associated with Pluronic® F127. Enhanced 
cytotoxicity due to the use of Pluronic® F127 may potentially become an 
exploitable feature for novel chemotherapeutic development in the future. 
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CHAPTER ONE 
 
INTRODUCTION 
 
 
 
Hurtles in Chemotherapy Efficacy and Development 
 
     A malignant neoplasm is generally defined as a group of cells that have acquired 
uncontrollable cell growth through the stimulation of their cell cycle [1]. Furthermore, 
these cells have developed methods towards evasion of cell death, stimulation of 
angiogenesis, and invasion of tissues through metastasis [1-2]. Chemotherapeutic agents 
work to stimulate alternative mechanisms of cell death in these neoplastic cells while 
maintaining minimal collateral damage of non-neoplastic cells. Therefore, the ideal 
chemotherapeutic would be equally potent and target specific. However, there are 
multiple pharmacokinetic and pharmacodynamic considerations when optimizing the 
function and efficacy of a particular chemotherapeutic.  
     Pharmacokinetics (what the body does to the drug) is defined as the absorption, 
distribution, metabolism, and secretion of a drug from a physiological system while the 
pharmacodynamics (what the drug does to the body) is defined as the biochemical 
influence of a drug on a physiological system and its mechanism of action [3]. Although, 
the efficacy of a chemotherapeutic depends on several factors, in a chemotherapy patient, 
it is the pharmacokinetics that affects the pharmacodynamic functions of the drug. For 
instance, even if a particular novel drug candidate shows excellent pharmacodynamic 
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properties in vitro, in vivo it may have poor solubility in the physiological environment, 
and therefore poor circulatory bioavailability.      
     A researcher must consider the many pharmacokinetic characteristics of a drug when 
attempting to develop new or improved chemotherapeutic agents. First, it is important to 
consider the absorption and distribution of the drug in an in vivo model. The absorption 
and distribution of drug in the blood stream are dependent on several factors but none so 
much as that of drug solubility [3-4]. For instance, Aspirin is insoluble in the acidic pH of 
the digestive juices in the stomach. However, when the drug enters the lumen of the small 
intestine, it is solubilized by the neutral and alkaline aqueous environment. Therefore, the 
rate of dissolution is the dependent step of drug absorption through the lumen of the 
small intestine and into the circulatory system [3]. The amount of drug that actually 
reaches the circulatory system from the gastrointestinal tract must then pass through the 
portal vein and into the liver before it is able to be distributed in the systemic circulation. 
The liver is the main organ responsible for the cleansing of the components of the 
circulatory system. Relative to drugs, the liver is involved in the metabolism or 
biotransformation of a drug into a more soluble, inactive, or even more active forms.  
     Although there exist several ways to optimize both the pharmacokinetic and 
pharmacodynamic specifications of chemotherapeutics, there are still several cellular 
defensive mechanisms that may avoid the pharmacodynamics of a chemotherapeutic 
agent. Cells that are able to mediate this pharmacodynamic evasion are termed drug-
resistant or multidrug resistant if this pharmacodynamic evasion occurs with a variety of 
chemotherapeutics. 
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Decreasing Chemotherapy Efficacy via Multidrug Resistance 
 
     Multidrug resistance is one of the leading causes for modern chemotherapy failure and 
is of particular importance in cancers where chemotherapy is amongst one of the few 
ways to manage the cancer. Multidrug resistance is characterized by the ability to avoid 
the cytotoxic effects of a particular drug and is caused by several factors. For example, a 
chemotherapeutic may initially kill those cells that are particularly sensitive to the 
chemotherapeutic agent, leaving behind cells that may have a resistance to the drug. Over 
time, when the cancerous cells have grown back to a detectable amount, the majority 
contains the similar drug-resistant factors that contributed to the lack of chemotherapeutic 
potency in the primary treatment. Therefore, when the chemotherapeutic is reintroduced, 
or even if it had been administered over a continuous and prolonged period, the cancer 
appears to respond less. 
     Another mechanism towards cellular multidrug resistance is through the expression of 
drug efflux pumps such as the P-glycoprotein (Pgp) and multidrug resistant protein 
(MRP) [5-6]. These ATPase drug efflux pumps are responsible for expelling 
chemotherapeutic drugs from within the cell before they are able to reach their target. 
Although these drug efflux pumps may be beneficial to cancer cell survival, they may 
also be found in normal cells. For example, cells in the liver, gastrointestal gland, and the 
renal tubules of the kidney highly express Pgp pumps which expel small molecules 
across their cellular membranes. However, when they are expressed in cancerous cells, 
they gain the potential ability to expel the chemotherapeutic. 
     The expression of these drug efflux pumps has been shown to correlate with the extent 
of drug resistance. For instance, using selective DNA transfer from a drug-resistant cell 
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line that expressed Pgp pumps into a cell line that was not drug-resistant, the DNA 
recipient gained a degree of drug resistance due to Pgp gene expression [5, 7]. A similar 
approach was used to show that expression of MRP in lung cells was correlated with drug 
resistance [5]. As a result, there are many pharmaceutical companies that have formulated 
drugs that target the function and/or expression of these drug-resistant proteins. For 
example, Vertex has produced Incel which blocks both Pgp and MRP in vitro, and 
thereby restores tumor chemotherapy sensitivity by increasing drug concentration within 
the cell [5]. However, normal cells also express these drug efflux pumps and are 
necessary for maintaining physiological homeostasis.  
     Since the drug-resistant proteins have been shown to correlate to drug resistance, it 
has been postulated that the inducible resistance through factors such as DNA transfer 
can become beneficial to cells that were not targets of the drug. More specifically, 
chemotherapy often targets rapidly replicating and differentiating cell lines (such as those 
of involved in hematopoiesis) which may or may not require the regulation of 
chemotherapeutic doses in order to allow for their restoration. If the drug-resistant 
properties given by these drug efflux pumps can be inducible into these hematopoietic 
cells, the negative side effects seen in many chemotherapy patients will be reduced. Titan 
Pharmaceuticals have already undertaken this idea in their creation of MDRx1 which can 
induce multidrug resistance in blood progenitor stem cells after Pgp gene insertion [5].          
 
 
Nanomaterials and Pluronics®: Improving Drug Delivery 
 
     Overall, increasingly efficacious chemotherapeutics must mediate their biochemical 
influence with potency, accuracy, and with aversion towards the development of 
5 
multidrug resistance; although they themselves are not the effecter compound, 
nanomaterials are beginning to show promise in being able to assist chemotherapeutics 
towards this goal. The reason why nanomaterials are currently making their way into the 
clinical realm of pharmacology is due to their many unique pharmacokinetic and 
pharmacodynamic properties. Some of the main nanomaterials of clinical interest are 
gold nanoparticles, liposomes, and nanomaterial based surfactants [8]. Together with 
their drug they behave as drug carriers, increasing both drug potency and accuracy.   
     Gold nanoparticles are inert and nontoxic gold particles surrounded by an organic or 
biomolecular monolayer, allowing for the conjugation of targeting ligands and drugs [8-
10]. As such, gold nanoparticles can be constructed to increase the pharmacokinetic 
characteristics of a particular drug. Furthermore, gold nanoparticles contain unique 
photochemical characteristics that allow for the controlled physical manipulation of their 
shape and size [11]. For example, it has been shown that upon near-infrared laser 
radiation of engineered hybrid polymeric gold nanoparticle drug capsules, there was an 
alteration in the particle shape, capsule rupture, and drug release at a specific site [12]. 
Similar controlled drug release mechanisms have been shown to work for DNA [13]. 
Liposomes are also capable of performing similar functions. Liposomes are phospholipid 
bilayer vesicles capable of encapsulating cargo within its interior. Hence, liposomes have 
been used as drug delivery vehicles for both hydrophilic and hydrophobic drugs. Not only 
are liposomes inert, biocompatible, nontoxic, and able to avoid immune responses, they 
can also be mass produced in the pharmaceutical industry [14-16]. Like gold 
nanoparticles, they are also able to become functionalized with targeting ligands that may 
increase tissue specificity. For instance, customization of membrane lipid composition 
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and charge of the liposomes allows for the increased drug uptake across physiological 
barriers such as that in the brain. A class of nanomaterial based surfactants called 
Pluronics® work in a similar way to liposomes in that they are able to act as drug carriers, 
improving pharmacokinetics and biodistribution of particular drugs [17].  
     Pluronics (PL) are a class of self associating, amphiphilic, tri-block copolymers with 
hydrophilic ethylene oxide (EO) and hydrophobic propylene oxide (PO) blocks and like 
the other nanomaterials discussed, they are able to be functionalized to improve their 
target efficacy. In polar solvents, they self associate into micelles at various 
concentrations based on their engineered chain composition and length, defining the 
degree of their amphiphilicity. As a result of their amphiphilicity, at high enough 
concentrations, the polymer unimers self-associate into micelles which contain both a 
hydrophilic and hydrophobic regions. The concentration at which this occurs is called the 
critical micelle concentration (cmc) and has been shown to be dependent on temperature 
[18-20]. This unique characteristic has been utilized to solubilize and transport 
hydrophobic drugs within the hydrophobic core of the PL micelles. For example, Kwon 
and others used in vitro and in vivo studies that showed increased solubility and 
bioavailability of the water insoluble drug genistein when encapsulated in PL F127 [21]. 
PLs have also been shown to increase the biodistribution of water soluble drugs. For 
example, through in vitro and in vivo experiments, Valle and others shown that the 
pharmacokinetics and biodistribution of doxorubicin increases when encapsulated in a 
formulation of PL L61 and F127 [22].  
     In addition to being good candidates for drug delivery systems, PLs are also being 
evaluated for their ability to exhibit synergistic effects along with their cargo drug, 
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avoiding multidrug resistant pathways [17]. For example, Kabanov and others have 
determined that the formation of micelles decreased the uptake of these tri-block 
copolymers in the liver without affecting total clearance in the kidney [17]. As a result, 
oral admissions of PL/drug conjugates are better able to avoid metabolic bio-
transformation and/or deactivation in the liver while later avoiding the side affects 
associated with low clearance rate of the drug [17]. PLs are also believed to be able to 
alter the microviscosity of tumor membranes and their surrounding vasculature, further 
increasing their already high permeability, making them of increasing interest in 
chemotherapeutics. Given that membrane protein stability and conformation are largely 
dependent on membrane integrity, the features of PL could also be used to show 
membrane protein inhibition [23-27]. Using FRET analysis of PL P85 concentrations 
below their cmc, it was shown that the P85 unimers largely associated with the lipid rafts 
of Pgp efflux pumps. Enzyme kinetics then showed decreased activity of the pumps along 
with decreased ATP levels [17]. Since, MRP efflux pumps are not associated with lipid 
rafts, there was little effect observed. PL P85 and other PL unimers have also been shown 
to affect cellular respiration by trans-locating into the mitochondria [16-17]. Here, they 
disrupt mitochondria membrane activity, leading to the downstream inhibition of the 
electron transport chain and ATP synthase [17, 25-31]. Furthermore, it has been shown 
that use of a doxorubicin/PL P85 conjugate significantly increases pro-apoptotic genes as 
compared to the use of doxorubicin alone; one possible explanation being the 
accumulation and release of Cyt c. [32]. 
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Need for Alternative Adjuvant Therapy for a Particularly Lethal 
Cancer 
      
     As of the 2010 cancer statistics published in the journal CA: A Cancer Journal for 
Clinicians, A poll taken in 2007 shows cancer as the second most leading cause of death 
in the United States [33]. A comparison of those cancer related deaths showed that 
among the more common lethal cancers such as lung and bronchus, stomach, colon and 
rectum, prostate, uterus, ovary, breast, pancreas, leukemia, and liver cancers, cancer of 
pancreas remains the 4th most common cause of cancer related death in males and 
females [33]. Furthermore, the data suggests little decrease in pancreatic cancer death rate 
since 1930 [33]. 
     Pancreatic cancer spreads quickly to the adjacent tissues such as the neural tissue, 
duodenum, portal vein (drains blood from the gastrointestinal tract and spleen to the 
liver), superior mesenteric vein (drains blood from the small intestine and terminates 
behind the pancreas where it merges with the splenic vein to form the portal vein), and 
regional lymph nodes. When localized in the pancreas, there are several resection options 
depending on the location of the primary tumor and degree of metastasis. For example, 
when the tumor is localized in the head of the pancreas, pancreatoduodenectomy (PD), 
subtotal stomach-preserving pancreatoduodenectomy (SSPPD), or pylorus-preserving 
pancreatoduodenectomy (PPPD) are performed [34-36]. Likewise, when the tumor is 
localized in the body and tail of the pancreas, distal pancreatectomy (DP) with 
splenectomy is performed. When the tumor is localized in the head of the pancreas, PD is 
preferred above the other types of resection methods. However, surgery alone does not 
appear to notably increase survival rate of patients. It is therefore recommended that 
patients also go through chemotherapy or chemoradiotherapy [36].  
9 
     Currently, chemotherapy and chemoradiotherapy are preferred over radiotherapy 
alone. This is because although radiotherapy is able to reduce the recurrence rate, it does 
not significantly increase the survival rate. Chemotherapy and chemoradiotherapy on the 
other hand do appear to provide a benefit to the overall survival rate in patients who have 
had resection of the primary tumor. Orthodox chemotherapeutics include gemcitabine 
and 5-fluorouracil (5FU) which mainly alleviate disease related symptoms such as pain. 
However, their use does not significantly increase the survival rate and therefore brings 
into question the apparently ambiguous affect on survival [36]. 
     Nevertheless, pancreatic cancer is particularly lethal due to its aggressive nature, 
relatively late onset of symptoms, and has an average life expectancy of 5 years after 
diagnosis. On average, 85%-90% of patients are diagnosed with locally advanced 
unresectable or metastatic stages of the cancer. Even for the patients who are able to 
undergo curative resection (10%-20%), only 10%-20% of them actually survive 5 years 
post diagnosis [36-41]. Hence, only about 5% of patients diagnosed with pancreatic 
cancer actually reach the 5 year life expectancy [42-43]. Although a patient may have 
curative resection of the cancer, the median survival rate for these patients is similar to 
that for patients with unresectable nonmetastatic pancreatic cancer. Given these facts, 
more innovative and efficacious detection and treatment methods need to be developed. 
 
 
Proliferation of Non-neoplasic Cells, Neoplastic Cells,  
and the Biochemical Role of Chemotherapeutics 
 
     Contributing the aggressiveness of pancreatic cancers to any set of factors such as 
genotype and phenotype is difficult [44-46]. However, what is common between the vast 
majorities of pancreatic adenocarcinoma cell lines is their loss of cell cycle regulation. 
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Excluding gamete cells, normal non-neoplastic cells replicate from the consecutive cell 
cycle process of cell interphase and mitosis (Figure 1). Interphase itself is divided into 
three sub-stages: G1, S, and G2. After a mitotic division of a cell, it enters the first phase 
of interphase called G1. Here, the cell matures and awaits growth signals or favorable 
environmental conditions in which it is appropriate for another round of cell division. 
Given desirable conditions, the cell may then begin to replicate its DNA. This phase of 
the cell cycle is called the S-phase and commits the cell to finish replication. Upon 
replication of cellular DNA, the cell enters the last phase of interphase called the G2-
phase. Here, the cell makes preparations for mitosis such as producing the microtubules 
necessary for arranging and separating homologous chromosomes during the mitotic 
phase (M). Cell cycle phase checkpoints ensure the series of events and performed both 
efficiently and with fidelity. If these cell phase checkpoints encounter problems that 
significantly effect the parent and/or daughter cells, the cell cycle is arrested in that 
particular phase of the cell cycle.     
     The process of cell division is largely dependent on a class of proteins called cyclin-
dependent kinases (Cdk) that when activated by their cyclin, promote the transcription of 
genes necessary for the stages of the cell cycle [1, 47]. In each cell, there are four known 
classes of cyclins, each defined by their Cdk at individual stages of the cell cycle. For 
instance, in non-neoplastic cells, favorable conditions lead to the activation of G1-Cdk 
during the G1-phase of the cell cycle. When activated, it is capable of promoting the 
transcription of G1/S-cyclins, which then activate G1/S-Cdk. Upon its activation, G1 ends 
and the cell becomes committed to initiate DNA replication. S-cyclins are also produced 
in the G1-phase which is necessary for the activation of S-Cdk in the S-phase where DNA  
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Figure 1. Phases of the cell cycle and their respective cyclins and cyclin partners. Also included are a 
few representative cell cycle checkpoints capable of inducing cell cycle phase arrest (as represented 
by lines ending perpendicularly). 
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replication occurs. Finally, Inhibition of DNA replication, initiation of the G2-phase, and 
progress through the ending stages of mitosis is directed by M-Cdk and its protein 
counterparts. M-cyclins produced during between the G2 and M phase help support their 
activity. 
     The processes in the cell cycle contain several complex, and sometimes antagonistic, 
regulatory components in order to maintain order, necessity, and quality in cell division; 
the following are only able to show an over simplified description of these regulatory 
mechanisms and are summarized in Figure 2. For example, the activity of Cdks 
throughout the cell cycle may become modified through phosphorylation by kinases such 
as Wee1 and Cdc25 phosphatase [47]. Other regulatory proteins are capable of either 
directly binding to and inactivating their targets or causing their downstream degradation. 
For example, in the G1-phase of the cell cycle, a Cdk inhibitory protein p27 directly binds 
to and inactivates G1/S-Cdk and S-Cdk [47]. In the G1 and S phase there also exists 
ubiquitin ligases such as Skp, Cullin, F-box containing complex (SCF). Guided by 
phosphorylated targets throughout the cell cycle, SCF leads to the degradation of certain 
Cdk inhibitory proteins and G1/S-cyclins that control S-phase initiation [48-50]. Other 
ubiquitin ligases such as the anaphase-promoting complex (APC) lead to the downstream 
degradation of M-cylins and other mitotic regulators [51-52]. Its own activity varies at 
different stages of the cell cycle. Mutations in such regulators are the hallmarks for 
various types of cancers. 
     Gene regulation of components necessary for cell cycle progression is another way 
that non-neoplastic cells regulate their cell cycle. For instance, the gene regulatory gene 
E2F is responsible for the activation of promoters that encode for proteins required for S-
 13 
phase entry such as the G1/S-cyclins and S-cyclins [53]. However, during the G1-phase, 
the E2F regulatory retinoblastoma protein (Rb) binds to E2F, inhibiting its activity. Also 
inhibited in the G1-phase is Cyclin D of G1-Cdk by the Cdk inhibitory protein p16INK4A 
[1, 6, 54-55]. It is not until the favorable environment and/or proper growth signals does 
the G1-cyclin become activated by Cyclin-D [56]. When this occurs, the activated G1-Cdk 
phosphorylates Rb, inactivating it, and releasing active E2F. Relative to pancreatic 
adenocarcinoma, mutated p16INK4A is one of three commonly mutated cell cycle 
mediators in 90% of cell lines; mutated Ras and p53 being the other two [46, 54-55]. 
     However, E2F activity is also regulated through the activation of another gene 
regulatory protein called Myc which is the downstream product of MAP-kinase 
activation [57]. This process begins though the activation of a membrane bound GTPase 
Ras protein. Specifically, mitogen growth factors stimulate the activation of Ras upon 
which it binds GTP, becoming active, and mediating the phosphorylation of MAP-kinase. 
By unknown mechanisms, MAP-kinase is able to activate gene regulatory proteins that 
are involved in the downstream transcription of genes such as Myc [47]. Myc itself 
mediates the transcription of cellular proliferation proteins such as Cyclin-D. As a result, 
Cyclin-D activates G1-cyclin, which stimulates Rb phosphorylation and so forth. Myc 
also regulates E2F transcription factors and SCF protein subunits [2]. Since increased 
SCF increases p27 degradation, there is increased G1/S-Cdk activation. Mutations in the 
Ras protein, as seen in the majority of pancreatic adenocarcinoma cell lines, may lead to 
hyperactivity of the protein and therefore increased cell signals in favor of replication.  
     There are also means of regulating the effects of abnormal proliferation signals and 
DNA integrity after replication; p53 is the most known tumor suppressor gene 
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responsible for that purpose and is also mutated in the majority of pancreatic 
adenocarcinoma cell lines [2, 46, 54-55]. Normally, unphosphorylated p53 is bound to 
Mdm2 protein and is targeted for ubiquitination [58-59]. If phosphorylated, p53 and 
Mdm2 dissociate and it is able to transcribe Cdk inhibitory genes and mediate apoptotic 
pathways or cell arrest [60-61]. For example, high amounts of Myc often leads to the 
production of another cell cycle inhibitor protein called p19ARF [47]. This inhibitor 
protein is capable of binding to Mdm2, releasing p53, and allowing it to promote genes 
involved in apoptosis or cell arrest [62]. p53 also is present in the response to DNA 
damage. This is largely due to a series of cell cycle checkpoints that are activated by 
protein kinases in the presence of mechanical errors in cell cycle. For example, in the 
response to DNA damage, cell cycle checkpoint protein kinases decrease p53 affinity to 
Mdm2 through phosphorylation of p53 [63-64]. This activated p53 is then able to bind to 
promoters of genes that encode for Cdk inhibitor proteins such as p21, capable of 
inhibiting the cyclins and Cdk partners of the G1-Cdk complex [2]. 
     The goal of chemotherapeutics is to compensate for the defective components of a 
cancerous target's cell cycle physiology. Chemotherapeutic agents work optimally when 
stimulating cell death pathways in their target tissues while maintaining minimal 
collateral damage of non-neoplastic cells. There are two main processes of cell death: 
necrosis and apoptosis. Necrosis is often caused through traumatic injury to a cell, 
causing it to lyse and cause inflammation. Furthermore, the often digestive lysate of lysed 
cells may cause collateral damage to adjacent cells.  
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Figure 2. Summary of cell cycle regulatory mechanisms. Placement of text shows the relative phase of the 
cell cycle where the particular regulatory pathway is found. Arrows represent "activation by" while lines 
ending perpendicularly represent "inhibited by." Text in bold represent the mutations found in the majority 
of pancreatic adenocarcinoma cell lines 
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     In contrast to necrosis, apoptosis is the process of programmed and controllable cell 
death. Apoptosis functions through the use of cysteine proteases and unlike necrosis, it 
has many important physiological roles in maintaining homeostatic balance. For example, 
apoptosis is responsible for the elimination of old, unnecessary, or damaged cells under 
non-inflammatory conditions [1-2]. Apoptosis is also responsible for the maintenance of 
physiological homeostasis and embryonic anatomical development [2]. For example, 
apoptosis is responsible for the regulation of immune cells and the cells contributing to 
organ, tissue architecture, and bone development.  
     There are two main paths towards apoptosis: extrinsic and intrinsic signaling 
pathways. The extrinsic signaling pathway, or the death receptor mediated pathway 
involves the interaction of a death receptor with its ligand; two particular ligands capable 
of initiating the extrinsic signaling pathway are Fas ligand and TNF-α [65-66]. When the 
ligand comes into contact with the death receptor, FADD and procaspase-8 and -10 are 
recruited to the intracellular domain of the receptor, forming the death inducing signaling 
complex (DISC) [65-66]. This complex is capable of activating procaspase-8, which in 
turn is able to cleave and activate executioner caspases such as caspases-3, -6, and -7 [65-
66]. It is the executioner caspases that are able to induce cellular apoptosis.  
     The intrinsic signaling pathway does not require extracellular mediated activation of 
apoptosis; it is able to initiate apoptosis through intracellular signals such as cellular 
stress or DNA damage. Upon one of these intrinsic signals, there is a perturbation in the 
genetic expression of pro and anti-apoptotic proteins such as BAX and BCL-2 
respectively. When there is sufficient expression of the pro-apoptotic protein, the 
mitochondrial membrane begins to leak Cyt c and other apoptotic regulators that support 
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the apoptotic cascade [67]. The secretion of Cyt c itself leads to its aggregation with 
Apaf-1 and procaspase-9, forming the apoptosome which serves to activate procaspase-9 
into the initiator caspase-9 [67]. Caspase-9 is then able to activate the executioner 
caspases-3, -6, and -7 which lead towards apoptosis.        
  
 
Purpose of this Study 
 
     As mentioned previously, 5FU is used to treat pancreatic cancer but does not 
significantly increase the survival rate of patients. 5FU itself is an antimetabolite uracil 
analogue that is able to exhibit anticancer effects through incorporation into RNA and 
DNA. As a result, proper cell division and protein synthesis is affected due to 
misincorporation of the active cytotoxic metabolites of 5FU. The metabolism of 5FU 
occurs inside the cell. However, nearly 80% of 5FU is metabolized in the liver [68]. 
Here, dihydropyrimidine dehydrogenase (DPD) metabolizes 5FU into the inactive form 
called dihydrofluorouracil (DHFU) [69]. DPD is also found in other cells but at much 
lower concentrations. The fraction of 5FU that is not transformed into DHFU is 
converted into the active cytotoxic metabolites.   
     The overall ineffectiveness of 5FU in the treatment of pancreatic cancer may be 
described by the carcinoma's resistance to the drug itself. For instance, it has been shown 
that there is overexpresion of the multidrug resistance associated protein MRP5 in the 
two pancreatic adenocarcinoma cell lines PANC-1 and MiaPaCa-2 [70-71]. Furthermore, 
this protein has been shown to actively confer drug resistance towards 5FU in pancreatic 
adenocarcinoma and other cancerous cell lines [26, 71]. Research has also shown that 
PLs are capable of reducing these pumps along with other mechanisms that lead to poor 
drug effectiveness. The central hypothesis of this work is that by using these PLs as drug 
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carriers, the innate pharmacokinetic obstacles in target cells will be reduced or entirely 
evaded. Furthermore, by using these conjugates it is hypothesized that there will be 
observable and measurable phenotypic effects in target cells. This study explores these 
observable effects in the pancreatic adenocarcinoma cells lines PANC-1 and MiaPaCa-2. 
Cell viability experiments using alamarBlue® were performed in order to monitor any 
synergistic effect between PL and its drug. Any effect on cell cycle is monitored by flow 
cytometry. Microscopy was also used to visualize any phenotypic changes in cell 
viability.   
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
Materials 
     PL F127 was purchased from Sigma-Aldrich (St. Louis, MO). 5-flourouracil (99.0% 
purity), propidium iodide (PI), and  0.25% trypsin with 1mM EDTA without Ca2+ or 
Mg2+, and in balanced salt solution in modified Hanks’ were obtained from MP 
Biomedicals (Solon, OH). Ribonuclease A (RNase) was obtained from Fisher 
BioReagents (Fair Lawn, NJ). Fetal bovine serum (FBS), penicillin-streptomycin 
antibiotic solution, Hanks’ balanced salt solution (HBSS)/modified, without Ca2+ or Mg2+ 
and Dulbecco’s modified eagles medium (DMEM)/high glucose with 4.00 mM L-
glutamine 4500 mg/L glucose, and sodium pyruvate were purchased from Thermo 
Scientific HyClone (Logan, UT). Ethanol (purity 95.0%) was purchased from Acros 
Organics (Morris Plains, NJ). alamarBlue® was purchased from AbD Serotec (Oxford, 
UK). DMEM with L-glutamine and the pancreatic cancer cell lines MiaPaCa-2 and 
PANC-1 were obtained from ATCC (Manassas, VA). All phosphate buffered saline 
(PBS) solutions were prepared from powdered PBS, pH 7.4, and dissolved in ultra pure 
water from a Barnstead Nanopure Diamond purifier. 
 
 
Characterization of PL F127 
 
     The physical characteristics of PL F127 in solution where determined by fluorescence 
spectroscopy and a pyrene (99.0% purity) probe from Sigma-Aldrich (St. Louis, MO). A 
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7.2 µM pyrene solution was prepared from acetone and 333.0 µL of this solution was 
added to 40 5 mL glass vials. The acetone from these vials was allowed to evaporate 
overnight and 4 mL of different PL F127 concentrations were added to each, making 0.6 
µM pyrene in each vial. The PL F127 solutions added to these vials ranged from 
0.0001% to 20% (w/v) and were made from a 20% PL F127 stock solution in 10 mM 
PBS. Samples were incubated for at both 25°C and 37°C for at least 7 hrs prior to 
analysis.  
     A Photon Technology International Model T PTI spectrofluorometer (Brimingham, 
NJ) with a magnetic micro-stirrer and Peltier temperature regulator was used for all 
fluorescence measurements. The lamp, excitation, emission, and PMT slits were set at 
0.30, 0.20, 1.00, and 1.60 mm respectively. The excitation and emission spectra of PL 
F127 was read at 360 and 260 nm, respectively. The excitation and emission spectra for 
the pyrene probe was read at 395 and 335 nm, respectively. Data was mathematically 
represented using SigmaPlot 11.     
 
 
Preparation of Pluronic F127 and 5-fluorouracil for in vitro 
Experiments 
 
     Four PL F127 solutions were prepared from a 10% (w/v) solution of PL F127 in the 
media appropriate for the MiaPaCa-2 and PANC-1 cell lines. The 10% (w/v) PL F127 
solution was made by dissolving 1 g PL F127 in 10 mL media at 37°C. This solution was 
filtered using a Fisherbrand ® 0.22 µm filter (Pittsburg, PA). From this stock, a 5% (w/v) 
PL F127 solution was made by diluting 5 mL 10% (w/v) PL F127 with 5 mL of the 
appropriate media. From this 5% (w/v) PL F127 solution, 0.004, 0.002, 0.04, 0.02, 4.0, 
and 2.0 % (w/v) PL F127 solutions were made. The IC50 dose for each cell line was 
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determined to be 80 µM at 48 hrs (Data not shown) and was used in each experiment. 
Ten mg of 5-fluorouracil was dissolved in 10 mL of the appropriate media and filtered 
with a Fisherbrand® 0.22 µm filter. From this stock solution, a 320 µM solution was 
made. A 160 µM 5-fluorouracil solution was made from the 320 µM 5-fluorurasil 
solution by dilution of 5 mL with 5 mL of the appropriate media. 
 
 
Cell Culture and Plating 
 
      MiaPaCa-2 cells were grown in DMEM/high glucose supplemented with 4.00 mM L-
glutamine, 4500 mg/L glucose, sodium pyruvate, 50 mL FBS, and 5 mL penicillin-
streptomycin antibiotics. Cells were incubated at 37°C with an environment containing 
5% CO2. Likewise, PANC-1 cells were grown in DMEM supplemented with 4mM L-
glutamine, 50 mL FBS, and 5 mL penicillin-streptomycin antibiotics. Similarly, these 
cells were incubated at 37°C with an environment containing 5% CO2. Each cell line was 
seeded by a different person and did not account for cell doubling time: for the cell 
viability experiments using MiaPaCa-2, approximately 2000 cells were seeded using a 
standard from 0 to 6000 cells and for cell viability experiments using PANC1, 
approximately 1000 cells were seeded using a standard from 0 to 3000 cells. 
 
 
Cell Viability Analysis 
 
     Cell viability experiments were performed using the alamarBlue® assay and analyzed 
using a Bio-Tek FLx800 multi-detection microplate reader with the KC4 analysis 
program, (version 3.4). Plates were read at excitation and emission wavelengths of 530 
and 590 nm, respectively. Cells for each cell viability experiment were seeded in 96-well 
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culture plates supplied by Corning (Corning, NY) and allowed to incubate 2 days prior to 
the addition of drug. For each cell line, 3 separate plates were used indicating a 24, 48, 
and 72 hr time point at which cells would be analyzed. Six or more wells were given to 
each particular type of treatment. Separate plates treated for 48 hrs were also prepared for 
purposes of phase contrast imaging using the Olympus 1X71 microscope and Spot 
camera analysis program, version 4.6. Aside from wells dedicated to the control and 5-
flurouracil treatment alone, treatment layout consisted of PL F127 concentrations 0.001, 
0.01, 1, and 2.5% (w/v) PL F127 both with and without 80 µM 5-fluorouracil. Total well 
volumes were 100 µL. Upon day of analysis, 10 µL alamarBlue® was added and allowed 
to incubate for 5 hrs prior to reading. 
 
 
Cell Cycle Analysis 
 
     Cell cycle was monitored using a FACSCalibur flow cytometer and BD Cell Quest™ 
Pro, version 4.01. Each cell line was analyzed using a different plating method. For the 
MiaPaCa-2 cell line, approximately 50,000 cells were seeded in four vented 25 cm2 tissue 
culture flasks supplied by BD Falcon (Dickinson, UK). Likewise, 100,000 PANC-1 cells 
were seeded in a 12-well culture plates from BD Falcon. After a 48hr incubation period, 
cells were treated. Aside from the control and 5-fluorouracil flasks, cells were treated 
with 2.5% (w/v) PL F127 with or without 5-flourouracil. Separate flasks were prepared 
for readings at the time points 24, 48, and 72 hrs. Upon day of analysis, cells and their 
supernatant were centrifuged at 1500 rpm for 5 min and resuspended in 200 µL 10 mM 
PBS filtered through a 0.22 µm filter. 1.8 mL ice cold 70% ethanol was added dropwise 
while vortexing samples. Samples were stored on ice for 30 min and then in a -20°C 
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freezer until analyzed. Before analysis, samples were centrifuged at 1500 rpm for 5 min 
and resuspended in 400 µL filtered PBS. Ten mg RNase was dissolved in 10 mL 
ultrapure water and 50 µL of this RNase solution was added to each sample. Likewise, 50 
µL PI was added to each sample and was prepared by dissolving 4 mg PI in 10 mL 
ultrapure water. Samples were allowed to incubate at 37°C for 30 min before being 
analyzed by flow cytometry.  
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CHAPTER 3 
 
RESULTS 
 
 
 
Characterization of Pluronic F127 
 
     The chemical composition and temperature determines the aggregation properties of 
PL F127 [18-20]. To determine these aggregation properties at physiological conditions, 
fluorescence measurements were performed using a hydrophobic fluorescent pyrene 
probe. The fluorescence of the pyrene probe depends on the microenvironment of its 
surroundings [72]. Using this characteristic, a pyrene probe was inserted in several 
concentrations of PL F127 in order to determine its phase characteristics. Figure 3 shows 
these changes in fluorescence for both 25 and 37 °C at λex = 335 nm.  
     The data in Figure 3 was represented in two ways. First, the integrated areas from I350-
I500 were calculated and plotted as a factor of PL F127 concentration (A). Since 
fluorescence intensity of the hydrophobic pyrene probe depends on its thermodynamic 
stability in solution, the intensity is higher at micellar concentrations of PL F127. 
Specifically, there are phase changes leading to the formation of PL micelles at higher 
concentrations of PL F127. As a result, the hydrophobic pyrene probe is capable of 
becoming stabilized in the hydrophobic core of the micelle. This stabilization is 
represented by higher emission intensities, and greater areas under the emission curves. 
The inflection point in the sigmoid curve represents the unimer to micelle phase change 
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of PL F127. This cmc value is around 0.01-0.1 % PL F127 (w/v) at 37 °C and around 
0.1-1.0 % PL F127 (w/v) at 25°C. 
     The data in Figure 3 was also represented as pyrene I372/I385 ratios (B). These ratios 
have been shown to correlate with the microenvironment of the pyrene [73-74]. 
Depending on the solvent polarity, the fluorescent intensity of two bands at 372 and 385 
either increase or decrease. Specifically, as the hydrophobic pyrene probe is stabilized in 
a more hydrophobic environment, the I385 increases. Thus, at higher micellar 
concentrations of PL F127, the pyrene probe is stabilized in the hydrophobic core of the 
PL F127 micelle, increasing the probe's I385, and decreasing the I372/I385 ratio. Again, the 
inflection point in the sigmoid curve represents the unimer to micelle phase change of PL 
F127. In this representation of the data, the cmc occurs around 0.01-0.1% (w/v) at 37 °C 
and around 0.1-1.0 % (w/v) PL F127 at 25 °C. 
 
 
Figure 3. Changes in pyrene fluorescence at various PL F127 concentrations. (A): 
changes in area under pyrene fluorescence (I350-I500). (B): Changes in the ratio of the first 
and third pyrene fluorescent intensity peaks (I372/I385). Fluorescence intensity was 
monitored at λex = 335 nm. 
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Evaluation of Cell Viability 
     Since the pro-apoptotic effects of PL are observed at different molecular formations 
depending on their chemical structure, it was important to first observe the effect of PL 
F127 at concentrations above and below the cmc, with and without of 5FU. Since the 
cmc of PL F127 was centered around 0.1% (w/v) under physiological temperatures, 
concentrations of 0.001, 0.01, 1.0, and 2.5% (w/v) PL F127 were used to fulfill this 
purpose in the following experiments. In vitro cell viability experiments using two 
pancreatic adenocarcinoma cell lines were performed to test for synergism between PL 
F127 and 5FU. The MiaPaCa-2 and PANC-1 cell lines selected were based on their 
sensitivity and resistivity towards current chemotherapy treatments. PL F127 was used as 
a hydrophilic surfactant towards drug solubilization of 5FU. The IC50 concentration of 80 
µM 5FU at 48 hrs was used as a comparison. Any synergistic effect would be compared 
to that of the control and 5FU alone. These experiments were performed using 
alamarBlue® (Invitrogen). 
     Figure 4 represents the results from the cell viability experiments performed on the 
more sensitive cell line MiaPaCa-2. The use of 80 µM 5FU significantly lowered the cell 
viability of MiaPaCa-2 by 40% as compared to the control (p < 0.001). The effect of PL 
F127 alone on MiaPaCa-2 cell viability largely relied on the concentrations above 0.01% 
(w/v)  and did not show any significant influence at the lowered conentrations. For 
instance, the use of 2.5% PL significantly reduced cell viability by 30% as compared to 
the control (p < 0.001). When both 80 µM 5FU and concentrations of PL F127 above 
0.01% (w/v)  were used, there was an enhanced cytotoxic effect towards as compared to 
the control and 80 µM 5FU alone. For instance, the use of 80 µM 5FU with 1% PL F127 
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led to a nearly 60% decrease in cell viability as compared to the control (p < 0.05); 
making the combination more cytotoxic by nearly 20% as compared to the use of 5FU 
alone. Likewise, the use of 80 µM 5FU with 2.5% (w/v) PL F127 led to a 70% decrease 
in cell viability as compared to the control (p < 0.001); making the combination more 
cytotoxic by nearly 30% as compared to the use of 5FU alone. We observed that the use 
of 0.01% PL F127 and 80 µM 5FU had no significant effect on cell viability. Even in the 
presence of 5FU, the effect was not significantly different as compared to the control. 
Furthermore, this treatment led to a 50% enhancement of cell viability as compared to the 
use of 5FU alone (p < 0.001). 
     
 
 
 
 
 
 
 
 
Figure 4. 48hr cell viability for MiaPaCa-2 treated with 5FU and PL F127 at concentrations 
below and above the cmc. (Mean ± S.D., n=18. *** and * represent p < 0.001 and p < 0.05 
respectively) 
 
 
      Figure 5 represents the results from the cell viability experiments performed on the 
more resistant pancreatic adenocarcinoma PANC-1 cell line. For purposes of simplicicity, 
not all significant differences are shown on the chart (See Appendix B for full summary). 
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Overall, the addition of PL F127 above and below 0.01% (w/v) did not significantly 
enhance cell cytotoxicity as compared to the control or the effect of 5FU alone. However, 
certain trends were similar to those seen from the MiaPaCa-2 cell line. The use of 80 µM 
5FU significantly lowered the cell viability of PANC-1 as compared to the control by 
more than 50% (p < 0.001). This effect was maintained when combined with PL F127 (p 
< 0.001 for each concentration of PL). For instance, the use of 80 µM 5FU with 0.001, 
0.01, 1, and 2.5% PL F127 led to a 50%, 50%, 30%, and 60% decrease in cell viability as 
compared to the control, respectively. The addition of PL F127 at concentrations above 
and below the cmc to 5FU, however, did not significantly enhance an effect on viability 
as compared to the use of 5FU alone. 
       
 
 
 
 
 
 
 
 
Figure 5. 48hr cell viability for PANC-1 treated with 5FU and PL F127 at concentrations below 
and above the cmc. (Mean ± S.D., n=18. *** represents p < 0.001) 
 
 
     Each cell line used in the cell viability experiments showed a similar  response 
towards 80 µM 5FU. This effect was significantly maintained when combined with PL 
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F127 except at 0.01% for MiaPaCa-2 where the viability was similar to the control. Both 
cell lines also showed similar responses to all concentrations of PL F127 when used 
alone. Furthermore, both cell lines showed a significant decrease in viability in response 
to 2.5% PL alone as compared to the control (p < 0.001).  
 
 
Microscopy of Cell Viability Data 
 
     Phase contrast images were taken at 48 hrs, under the same experimental conditions 
from the cell viability experiments, to visually monitor the effect of PL F127 and 5FU on 
the cell viability. Figure 6 shows a representative collection of MiaPaCa-2 phase contrast 
images. There is qualitative agreement between the phase contrast images of MiaPaCa-2 
and its cell viability data. As compared to the control, cells treated with 80 µM 5FU show 
decreased number. Furthermore, cells treated with both 80 µM 5FU and concentrations 
1% and 2.5% PL F127 show an enhanced effect on cell viability as compared to the use 
of 5FU alone. Likewise, phase contrast images of PANC-1 under the same conditions as 
those in the cell viability experiments show no obvious differences in cell number (Figure 
7). 
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Figure 6. 48 hour phase contrast images of MiaPaCa-2 cell lines treated with PL F127 and 5FU. 
 
Figure 7. 48 hour phase contrast images of PANC-1 cell lines treated with PL F127 and 5FU. 
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Evaluation of Cell Cycle 
     Cell cycle is regulated through various mechanisms that are dependent on both 
internal and external stimuli. These alterations in cell cycle can be monitored via flow 
cytometry. By measuring cell DNA content, flow cytometry is capable of measuring cell 
percentages in particular phases of their cell cycle. From the cell viability data there 
appears to be an enhanced effect on viability in the treatment of MiaPaCa-2 cells with 
5FU and concentrations of PL F127 above the cmc as compared to the use of 5FU 
treatment alone. Therefore, any effect observed on cell cycle from 5FU should be 
enhanced in combination with micellar concentrations of PL F127. In these experiments, 
propidium iodide was used to measure the percentages of cells in particular phase of the 
cell cycle when treated with 5FU and micellar concentrations of PL F127 for 48 hrs. Both 
MiaPaCa-2 and PANC-1 cell lines were used using the same experimental conditions as 
those in the cell viability studies. Along with 80 µM 5FU, only 2.5% PL F127 was used 
to observe any effect on cell cycle since the effect on cell viability was greatest at this 
concentration. 
     Table 1 shows the summary of cell cycle data for MiaPaCa-2. Cells that are sub G1 
account for cells that are either going through apoptosis, necrosis, or as cell debris. From 
the data in Table 1, it can be seen that 5FU and 2.5% PL alone did not significantly 
induce cells into cell death as compared to the control. However, the combination 
treatment of 2.5% PL F127 and 5FU significantly induced cell death as compared to the 
control. Furthermore, the percentages of cells induced into cell death due to the 
combination of 2.5% PL F127 and 5FU was significantly higher compared to the 
percentages of cells killed from PL F127 alone. Maturing cells that await another round 
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of mitosis are kept in the G1 phase of the cell cycle. As seen from Table 1, there were 
significantly less cells found in this phase of the cell cycle after treated with 5FU alone 
and the combination of 2.5% PL F127 and 5FU. As compared to the control, since there 
were significantly higher percentages of dead cells due to the combination treatment of 
2.5% Pl F127 and 5FU, it would be expected that less cells would also be able to go 
through another round of cell cycle. However, the use of 5FU alone did not significantly 
increases the percentages of dead cells as compared to the control. Overall, there were no 
significantly increased percentages of cells, indicating cell arrest, in any of the phases of 
the cell cycle, making it not possible to characterize the effect of PL F127 on cell cycle. 
In PANC-1 cells, there were no significantly increased or decreased percentages of cells 
in any of the phases of the cell cycle as compared to the control and the various 
treatments (Table 2). 
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Table 1. Summary of cell cycle data for MiaPaCa-2. Values are expressed as percentages 
of cells in a particular phase of the cell cycle (Mean, n=3. Superscript number pairs show 
values that are significantly different from each other, p < 0.05). 
 
 Control 80 uM 5FU 
2.5% PL 
F127 
2.5% PL F127 
+ 80 uM 5FU 
Sub G1 5.07 1 27.06 14.55 2 45.50 1, 2 
G1 61.98 3, 4 29.78 4 48.54 25.54 3 
S 8.16 18.85 6.95 10.5 
G2/M 18.46 13.6 16.8 11.81 
Poly-
ploidic 6.28 11.28 13.39 6.92 
 
 
Table 2. Summary of cell cycle data for PANC-1. Values are expressed as percentages of 
cells in a particular phase of the cell cycle (Mean, n=3. Superscript number pairs show 
values that are significantly different from each other, p < 0.05). 
 
 Control 80 uM 5FU 
2.5% PL 
F127 
2.5% PL F127 
+ 80 uM 5FU 
Sub G1 4.14 31.43 40.69 40.07 
G1 57.12 15.61 28.16 31.52 
S 12.74 29.32 9.27 10.7 
G2/M 20.98 18.77 17.85 14.88 
Poly-
ploidic 4.93 4.9 4.05 2.91 
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CHAPTER 4 
 
DISCUSSION 
 
 
 
Explaining Cytotoxicity through Phenotype and Genotype  
 
     There are several contributing factors that may lead to the varying degrees of drug 
resistance and cell propagation. For instance, cell adhesion properties, affect tumor 
growth, metabolism, and metastatic potential [44, 46]. The aggressiveness on the other 
hand may be contributed to the cancer's invasive and angiogenic potential [44, 75-76]. 
However, correlating such phenotypic characteristics to the chemosensitivity of the 
individual cell lines used in this study requires a more detailed analysis. Unfortunately, 
there is currently a lack of research that consistently correlates genotype to phenotype 
and cell behavior of pancreatic cancer cell lines [44-46]. 
     The genotype defines a particular type of pancreatic cancer cell line. However, 
research has shown that the genotype, phenotype, and cell behavior can vary between the 
same cell line derived from an organ system [44-46]. For instance, the time at which it 
takes for the population of cells to double their current number varies in between studies: 
18-40 hours for MiaPaCa-2 and 25 to 52 hours for PANC-1 [45-46, 77-78]. Doubling 
time depends on several criteria such as the availability of growth factors, which is 
inadvertently related to the degree of cell compaction [45]. Although doubling time 
depends on initial seeding population, doubling time variability between studies can be 
contributed to several other factors. For example, culture conditions, passage duration, 
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and passage time increase probability of genetic drift from the primary cell line source, 
leading to changes in cellular morphology, genetic expression, phenotype, and overall 
cell behavior [44, 79-81]. In this study, passages from two to five were used in order 
minimize these experimental and technical errors in cell culture.  
     Cell behavior and response to chemotherapeutics has also been shown to depend on 
the integrity of culture conditions [80]. In this study, the response of both the cell cultures 
to 5FU was relative to their IC50. This IC50 value was 80 µM and was the same for each 
cell line. However, the reported  IC50 dose varies between several studies which in 
themselves vary from each other. For example, some studies have determined IC50 doses 
ranging from 4 to 38 uM 5FU for MiaPaCa-2 cells [45, 82-83]. In our experiments, we 
have determined the IC50 dose to be double these concentrations. These differences in 
chemosensitivity are likely do to the variations in methodology between studies. The 
question then becomes from what cell culture method is the cell behavior and 
chemotherapy responsiveness truly representative of each cell line.      
     Duxbury and coworkers used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay in order to determine the IC50 dose of 5FU in both MiaPaCa-2 and 
PANC-1 after 96 hrs [82]. Using these methods, they determined the IC50 to be 38 µM 
for MiaPaCa-2 and 62 µM for PANC-1. The MTT assay works in a similar manner as 
alamarBlue® in that it measures cell viability via components of cellular respiration. 
Normally, MTT is a soluble dye that is capable of passing through cellular membranes, 
including the mitochondria. However, MTT becomes insoluble after being reduced 
through the action of dehydrogenases and their cofactors [84]. After the insoluble product 
is solubilized, its optical density can be measured, which is proportional to the amount of 
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viable cells. However, and unlike alamarBlue®, by becoming reduced in the 
mitochondria, it puts an end to the flow of electrons in the electron transport chain [85]. 
Both this and the presence of the insoluble byproduct later induce cell death.  
     This extent of treatment prior to analysis may explain the variation with our own 
experiments and with the studies of others. For instance, it is hypothesized that longer 
incubation periods call for higher doses to account for the proliferation of cells over a 96 
hour period. If this were the case, researchers would run the risk of calibrating the IC50 to 
the chemoresistant cells. In other words, at high doses of chemotherapeutic, sensitive 
cells are killed, leaving behind the more resistant strain behind. The dose is then 
calibrated so that 50% of these cells, now resistant, are viable as compared to the control 
after 96 hours. On the other hand, the effect of smaller doses over a 96 hour period may 
be hidden by the degree of proliferation. Therefore, seeding density may also cause 
variation in the observed IC50. Still, these hypotheses appear to somewhat contradict our 
own data since we used shorter time points but still found the IC50 of 5FU to be higher 
than in this particular study. It does not however entirely exclude the possibility that the 
difference in the IC50 concentrations is due to the inadvertent selection of chemoresistant 
cells.  
     Shi and his colleagues, on the other hand used a Sulforhodamine B (SRB) assay in 
order to determine the IC50 for MiaPaCa-2. Using a 72 hour incubation period, they found 
the IC50 of 5FU for MiaPaCa-2 to be around 5 µM [83]. This particular assay works in an 
entirely different manner than alamarBlue® and MTT; instead of measuring viability 
through cellular respiration, SRB measures it through the protein content. Specifically, 
the SRB dye binds electrostatically and pH dependent wise to the basic amino acids of 
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cellular proteins [86]. By extracting and dissolving these dyed proteins, it is possible to 
measure their optical activity and correlate its degree to cell viability. It is until this stage 
of extraction that the SRB assay remains nondestructive.  
     The IC50 for 5FU in MiaPaCa-2 that was determined and used in our study was 16 
times more concentrated than that from Shi's studies. Likewise, Duxbury's studies 
determined an IC50 for 5FU in MiaPaCa-2 that was nearly 8 times more concentrated than 
the IC50 in Shi's study. A few methodological factors may be contributing to such 
variation amongst the literature and our own data. First, SRB depends on protein integrity 
and native structure [86]. However, a key feature of 5FU is its ability to cause 
modifications in tRNA and rRNA [87-92]. As a result, the availability of native protein 
structures with native basic amino acids can be expected to be altered in some way. It is 
therefore reasonable to consider that the SRB assay shows altered cell viability because 
of its misrepresented affinity to the denatured proteins. Second, each study used different 
seeding densities, allowing for various degrees of cellular responses to growth factors and 
other extracellular interactions [45]. Overall, the variation seen in the IC50 for 5FU in 
both MiaPaCa-2 and PANC-1 could depend on several factors, making it imperative that 
any conclusions in this work are kept relative to these specific experimental conditions.  
 
 
Cell Viability Data 
 
     The cytotoxicity of 5FU and PL F127 on MiaPaCa-2 and PANC-1 was assessed using 
the alamarBlue® cell viability assay. This dye measures cell viability via measurement of 
cellular respiration. Normally, this dye is blue but becomes pink after being reduced 
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during the final stages of the electron transport chain [85]. This color change indicates the 
activation of a fluorescent probe that is detectable at 530/590 nm.  
     Membrane and protein complexes in the mitochondria are known targets of PLs [18, 
21, 28-29, 58-59]. Even though there have not been any definitive studies that 
characterize the migration of PL F127 within the cell, it is still amphiphilic and may 
therefore have possible internal cell structure targets. Given the scenario where PL F127 
actually migrates to the mitochondria, it may be capable of altering mitochondrial 
membrane integrity and the conformations of protein complexes involved in cellular 
respiration. Since alamarBlue® depends on the integrity of the electron transport chain, 
the response from the dye  would be affected; less dye would be reduced and become 
fluorescent, indicating viable cells. Although the cells would indeed be in a state of 
stress, their lack of viability as shown from the dye may not be entirely representative of 
their overall viability. In summary, PL F127 would distort the results shown from the 
alamarBlue® cell viability assay. However, without conclusive data showing the 
migration abilities of PL F127 in MiaPaCa-2 and PANC-1, these suspicions can not be 
fully addressed.  
 
 
Cell Cycle Data 
 
     The main purpose of flow cytometry in this study was to characterize the effects seen 
from the cell viability data in terms of the phases of the cell cycle. However, cell cycle 
analysis using flow cytometry showed no significant differences in the phases of the cell 
cycle in both MiaPaCa-2 and PANC1 as compared to the control. It was expected that 
PANC-1 would show little change in its cell cycle, as compared to the control, since it 
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showed resistance to PL F127 in the viability experiments. However, these results appear 
contradictory when in comparison to MiaPaCa-2, where as compared to the control and 
the use of 5FU alone, there were significant changes in viability due to micellar 
concentrations of PL F127. Most importantly, where significant changes in cell viability 
due to 5FU alone as compared to the control were observed from the cell viability data, 
there was no significant effect on cell cycle. These observations were surprising for a few 
reasons. Therefore, in the following sections we will describe what was expected from 
these experiments and critically analyze the data for trends that may help future works 
that use similar experimental methods. However, the majority of these descriptions will 
include insignificant data from the flow cytometry experiments.  
     Before we begin the discussion, it is important to first mention that although it is 
based on statistically insignificant trends, it still largely relies on the integrity of the 
mechanics of cell cycle checkpoints. These checkpoints will be able to tell us in which 
phases of the cell cycle the cells are arrested, if not killed or poly-ploidic. However, it 
may be the machinery of the checkpoint itself that is affected in each cell line, 
contributing to its cancerous characteristics, and concealing the cell cycle arrest we may 
expect. As stated previously, one of the characteristic mutations in pancreatic 
adenocarcinoma cell lines are in p53. This tumor suppressor is not only responsible for 
cell cycle regulation but is also a component of the G1 to S phase cell cycle checkpoint 
[93-94]. Since this tumor suppressor is mutated in both MiaPaCa-2 and PANC-1, it may 
contribute to the insufficiency of cell cycle arrest. However, complete control of this 
checkpoint is not lost due to checkpoint mechanisms independent of p53 [95]. 
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Furthermore, p53 is by no means the only checkpoint component throughout the other 
phase checkpoints of the cell cycle. 
     Beginning this discussion with the control, the cell cycle data for the MiaPaCa-2 and 
PANC-1 showed that ~4 to 5% of the cells were sub G1, an area often indicating 
fragmented DNA from dead or dying cells. Likewise, each cell line had around 60% of 
its cells in the G1 phase. Since the majority of the cells are in this phase indicating the end 
of mitosis and cell division, we may deduce that the cells have received signals to alter 
cell cycle. This is a common response in molecular cell biology due to significant cell-to-
cell contact [1, 96-97]. A study using identical staining and analysis time points showed 
that nearly 50% of cells in each cell line were in the G1 phase [45]. Using these 
parameters they also measured the effect on cell cycle using common chemotherapeutics, 
including 5FU. From these experiments they were able to discern cells in apoptotic 
regions. In comparison to our data and methods, we may conclude that the high 
percentages of cells observed in the G1 phase in our cell lines may not entirely indicate 
significant influence in cell proliferation. Furthermore, we should be able to locate 
regions of significant changes in cell cycle. Other indicators of cell cycle progression are 
the S and G2/M phases of the cell cycle. The percentages of cells in these phases were 
similar in each cell line and also similar to previous studies [45]. 
     Next, we look at the effects of 5FU on cell cycle for MiaPaCa-2 and PANC-1. The 
treatment with 5FU in both cell lines was expected to yield different results from the 
control but also from each other due to individual chemosensitivity. [45, 71, 98]. 
Nevertheless, significantly increased percentages of cells in the S phase, indicating 
activation of a cell cycle checkpoint and induction of cell arrest, were expected since 5FU 
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affects both DNA and RNA fidelity. First, there was nearly five times the percentage of 
cells in the sub G1 phase in MiaPaCa-2 as compared to the control. In PANC-1, there was 
nearly eight times the percentage of cells in the sub G1 phase as compared to the control. 
Looking at the percentages of cells in the G1 phase in MiaPaCa-2 and PANC-1 showed a 
decreased percentage of nearly two and four times, respectively, as compared to the 
control. These numbers correlated to the percentages seen in the S phase of each cell line: 
nearly 2-3 times more than the control. MiaPaCa-2 cells also seemed to be more 
susceptible to poly-ploidy than PANC-1 as seen from the data. Since 5FU affects both 
DNA and RNA fidelity, critical structural and signaling components during mitosis could 
have been affected.  
     Next, the effects of 2.5% PL F127 alone will be discussed. From the cell viability data 
of both cell lines, 2.5% PL F127 was able to exert a cytotoxic effect similar to the degree 
seen by 5FU alone. In an attempt to explain this effect first through the cell cycle of 
MiaPaCa-2, we found results similar to that of the control; the difference being that 
treatment with 2.5% PL F127 caused an increase in the percentage of cells found in sub 
G1 and the poly-ploidic region. In comparison to the control, MiaPaCa-2 had nearly the 
same ratios of cell percentages passing from G1 to S to the G2/M. However, these 
percentages were lower after the PL F127 treatment due to the percentages found in sub 
G1 and the poly-ploidic region. Since the ratios of cells passing through the normal 
phases of the cell cycle were similar to the control, this data would suggest that those 
cells affected adversely by PL F127 were affected so by the influence on the structural 
components involved in the mechanical separation of cells. Due to PL F127s 
composition, we suspect that this effect is likely to cause perturbations of the cell 
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membrane and not from intracellular interactions [17, 23, 99-100]. However, the 
treatment of cells with PL F127 does not comparatively have as great of an effect on 
percentages in sub G1 as does 5FU alone.  
     When comparing the results of PANC-1 cells treated with 2.5% PL F127 with its 
control, we saw that the ratios of cells going from the G1 to S to the G2/M phase was not 
proportionate to those seen from the control. Furthermore, we saw that there were 
noticeably more cells in the sub G1 phase of the cell cycle. This makes these percentages 
difficult to interpret for a few reasons. First, we saw that percentage of cells in the G1 
phase was lower than the percentage found in the control. This would imply cell arrest in 
the G2/M phase of the cell cycle. However, when we compare the G2/M of the PL F127 
treated cells with the control, we see no noticeable differences between the two. 
Additionally, we can not explain the cytotoxic effect of PL F127 based on its ability to 
induce poly-ploidy since the percentages of cells in this region was nearly the same to 
that of the control. It is true that the majority of these descriptions of our cell cycle data 
use insignificant data. However, without any noticeable trends, and without further 
analysis, it can only be concluded that PANC-1 responds adversely to PL F127 in a 
manner that avoids detection using these methods. 
     The fact that 40% of the cells are counted as debris is of concern in regards to the 
ability of flow cytometry to accurately measure cell cycle. This is because at such high 
degrees of cell death, remaining cells are possibly those selected based on their tendency 
to be resistant and do not represent the true sample group. Degree of cell death can be 
contributed to a few factors: dose and time of treatment. However, since we wanted to 
examine the cytotoxic effect at a selected dose, the alternative would be to choose a 
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shorter time points at which to analyze the samples. This way, we are able to catch the 
process of cell cycle prior to mass cell death. In our experiments, we chose a time point 
of 48 hrs before cell cycle analysis. Perhaps a more reasonable time point to analyze the 
samples would be before 48 hrs. Being aware of this issue, we have performed 
preliminary studies using the time points 6, 12, 18, and 24 hrs (See Appendix). Although 
this experiment has only been performed once, it showed that even a 24 hour treatment 
may be too late to analyze samples. 
     Lastly, we compared the effect of combination treatment with the individual effect of 
2.5% PL F127 and 5FU. In MiaPaCa-2, we saw that there was a significantly increased 
percentage of cells that were sub G1 as compared to the control (p <0.01) and the use of 
PL F127 alone (p<0.05). We therefore need to identify either the presence or absence of 
cooperation between PL F127 and 5FU. In other words, do PL F127 and 5FU display 
synergism in their cytotoxicity?  
     The additive effect of 5FU and PL F127 towards cell percentages in sub G1 would 
imply that we are not observing an entirely new effect in MiaPaCa-2. Rather, we are 
observing the individual effect of both PL F127 and 5FU. However, the effect on poly-
ploidy disappears. It may be reasonable to conclude that the absence of the additive effect 
on poly-ploidy is due to alternative pathways that the combination treatment uses. 
Nevertheless, it must be pointed out that nearly half of the cells are counted as debris. On 
the other hand, PANC-1 does not show an additive effect on cell percentages in sub G1; 
only 40% are counted as debris. Either the combination treatment protects 60% of the 
cells or the additive cytotoxic effect of 70% (and likely more if we are considering that 
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we are observing the cell cycle of the more resistant cells after the PL F127 treatment) 
selects the more resistant cells at which only 40% are counted as debris.      
 
 
Conclusions 
 
     In this study we found that there was enhanced cytotoxicity of 5FU when used in 
combination with PL F127 at concentrations above the cmc. These effects were only seen 
in the chemosensitive cell line MiaPaCa-2 and not in the chemoresistant PANC-1 cell 
line. Furthermore, at very high concentrations of PL F127, there is significant cell 
cytotoxicity in both cell lines. From the cell viability and microscopy studies, this data 
would suggest that the combined treatment using 5FU and PL F127 at concentrations 
above the cmc for more sensitive pancreatic cancer cell lines is more effective than 
treatment with 5FU alone. However, any perturbations in cell viability could not be 
identified as a synergistic or additive.    
     Preliminary characterization of the two cell lines after treatment using flow cytometry 
did not significantly show any changes in cell cycle. These results are believed to be due 
to methodological errors in cell harvesting and in the flow cytometry instrument settings. 
However, the trends observed from the cell cycle studies do agree with the data seen from 
the cell viability experiments.  
 
 
Future Studies 
 
     The purpose of this study was to observe the effect of 5FU in combination with PL 
F127 and correlate any enhanced cytotoxicity to synergism. However, it did not explore 
means to characterize the effect of 5FU with PL F127. More specifically, the mechanism 
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at which 5FU acts as an antimetabolite has already been well characterized [68-69]. 
However, it is still unknown what role PL F127 plays in cell cytotoxicity. The future 
studies would therefore address the presence of synergism. 
     The first question would be the structural characteristics of the 5FU and PL F127 
mixture. For instance, where is 5FU partitioned when concentrations of PL F127 are 
above the cmc? Furthermore, is the dose of 5FU delivered to the cells enhanced when 
using concentrations of PL F127 above the cmc? One method in which this could be 
explored would be through use of solid dispersion. Although it is true that 5FU is 
relatively hydrophilic and water soluble, it is still theoretically capable of being dispersed 
in between the hydrophilic corona and hydrophobic core of the PL micelle [17]. For 
example, Kwon and others used solid dispersion to encapsulate genistein in PL F127 
micelles. After filtering to remove undissolved genistein, these micelles were freeze dried 
and weighed to measure loading capacity [21]. Micelle stability and cargo release were 
measured using a dialysis bag and HPLC. Using 5FU in the place of genistein, we could 
measure loading capacity and release to better identify the role of PL F127 in our study.  
     The second area of interest would be to identify the cytotoxicy of PL F127 alone. For 
instance, why do we see that at 2.5% PL there is a cytotoxic effect nearly equal to that of 
5FU alone in both cell lines? At concentrations of PL F127 high above the cmc, the 
micelles begin to reassemble and aggregate into gels [100]. Furthermore, the ability to 
form gels increases with increasing temperature [101-104]. Therefore one route could be 
to explore the possibility that at these high concentrations of PL F127, the extracellular 
environment alters the viscosity enough to disturb the kinetics involved in nutrient 
absorption and metabolite product secretion, inadvertently creating a state of starvation. 
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For reasonss mentioned previously, these unfavorable growth conditions would cause 
perturbations in phases of the cell cycle which could be monitored via flow cytometry. 
However, this does not reject the possibility that PL F127 micelles mediate a direct 
cytotoxic effect via altering membrane microviscosity or through adverse signaling 
cascades. 
     In order to differentiate the cytotoxic effect of PL F127 as either indirect or direct 
would require a means of locating PL F127 throughout the entire cell. One way to 
characterize the location of PL F127 when using concentrations high above the cmc 
would be to use fluorescence resonance energy transfer (FRET). For instance, when using 
a modified PL molecule as the donor and Cholera toxin B as the acceptor probe, 
Batrakova and coworkers observed an exchange of fluorescence localized on lipid rafts 
believed to be associated with Pgp pumps [17]. Using similar methods, it is believed we 
could create fluorescent donor and acceptor pairs for the lipids at various locations within 
the cell, i.e. the cell membrane or mitochondria. Although this will likely be an 
exhaustive study, it would allow us to localize the PL F127 and correlate its position with 
potential cytotoxic capabilities; for instance, localization in the mitochondria may be 
correlated with mitochondrial membrane microviscosity changes and thus perturbations 
in mitochondrial mediated apoptotic signaling.  
     After examining more qualitative means to better understand our data, it would be 
interesting to explore experimental conditions that take advantage of the physical 
characteristics of PLs. For example, there have not been any studies that take advantage 
of PL F127's ability to compartmentalize and deliver hydrophobic drugs in either 
MiaPaCa-2 or PANC-1. Mixtures of PLs also benefit pharmacokinetics and 
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pharmacodynamics by improving lipophilicity towards target cells [17, 22]. Knowing 
this, we could increase micelle hydrophobicity content through addition of more 
hydrophobic PLs such as L31, P85, and L61. As a result of the increased hydrophobicity 
content, cell membrane affinity requirements are met and drug delivery becomes more 
efficient. 
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APPENDIX A 
 
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON  
TESTS OF MIAPACA-2 CELL VIABILITY DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control vs 80 uM 5FU *** P<0.001 
Control vs 0.001% PL ns  P>0.05 
Control vs 0.001% PL/5FU *** P<0.001 
Control vs 0.01% PL **  P<0.01 
Control vs 0.01% PL/5FU  *   P<0.05 
Control vs 1% PL ns  P>0.05 
Control vs 1% PL/5FU *** P<0.001 
Control vs 2.5% PL *** P<0.001 
Control vs 2.5% PL/5FU *** P<0.001 
80 uM 5FU vs 0.001% PL *** P<0.001 
80 uM 5FU vs 0.001% PL/5FU ns  P>0.05 
80 uM 5FU vs 0.01% PL *** P<0.001 
80 uM 5FU vs 0.01% PL/5FU *** P<0.001 
80 uM 5FU vs 1% PL *** P<0.001 
80 uM 5FU vs 1% PL/5FU *   P<0.05 
80 uM 5FU vs 2.5% PL ns  P>0.05 
80 uM 5FU vs 2.5% PL/5FU *** P<0.001 
0.001% PL vs 0.001% PL/5FU **  P<0.01 
0.001% PL vs 0.01% PL **  P<0.01 
0.001% PL vs 0.01% PL/5FU **  P<0.01 
0.001% PL vs 1% PL ns  P>0.05 
0.001% PL vs 1% PL/5FU *** P<0.001 
0.001% PL vs 2.5% PL **  P<0.01 
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* represent the degree of significance and ns indicates a non significant comparison. 
 
 
0.001% PL vs 2.5% PL/5FU *** P<0.001 
0.001% PL/5FU vs 0.01% PL *** P<0.001 
0.001% PL/5FU vs 0.01% PL/5FU *** P<0.001 
0.001% PL/5FU vs 1% PL *** P<0.001 
0.001% PL/5FU vs 1% PL/5FU *** P<0.001 
0.001% PL/5FU vs 2.5% PL ns  P>0.05 
0.001% PL/5FU vs 2.5% PL/5FU *** P<0.001 
0.01% PL vs 0.01% PL/5FU ns  P>0.05 
0.01% PL vs 1% PL ns  P>0.05 
0.01% PL vs 1% PL/5FU *** P<0.001 
0.01% PL vs 2.5% PL *** P<0.001 
0.01% PL vs 2.5% PL/5FU *** P<0.001 
0.01% PL/5FU vs 1% PL ns  P>0.05 
0.01% PL/5FU vs 1% PL/5FU *** P<0.001 
0.01% PL/5FU vs 2.5% PL *** P<0.001 
0.01% PL/5FU vs 2.5% PL/5FU *** P<0.001 
1% PL vs 1% PL/5FU *** P<0.001 
1% PL vs 2.5% PL *** P<0.001 
1% PL vs 2.5% PL/5FU *** P<0.001 
1% PL/5FU vs 2.5% PL *** P<0.001 
1% PL/5FU vs 2.5% PL/5FU ns  P>0.05 
2.5% PL vs 2.5% PL/5FU *** P<0.001 
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APPENDIX B 
 
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON  
TESTS OF PANC-1 CELL VIABILITY DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control vs 80 uM 5FU *** P<0.001 
Control vs 0.001% PL *** P<0.001 
Control vs 0.001% PL/5FU *** P<0.001 
Control vs 0.01%PL *** P<0.001 
Control vs 0.01% PL/5FU *** P<0.001 
Control vs 1% PL **  P<0.01 
Control vs 1% PL/5FU *** P<0.001 
Control vs 2.5% PL *** P<0.001 
Control vs 2.5% PL/5FU *** P<0.001 
80 uM 5FU vs 0.001% PL *** P<0.001 
80 uM 5FU vs 0.001% PL/5FU ns  P>0.05 
80 uM 5FU vs 0.01%PL *** P<0.001 
80 uM 5FU vs 0.01% PL/5FU ns  P>0.05 
80 uM 5FU vs 1% PL *** P<0.001 
80 uM 5FU vs 1% PL/5FU *** P<0.001 
80 uM 5FU vs 2.5% PL ns  P>0.05 
80 uM 5FU vs 2.5% PL/5FU ns  P>0.05 
0.001% PL vs 0.001% PL/5FU *** P<0.001 
0.001% PL vs 0.01%PL ns  P>0.05 
0.001% PL vs 0.01% PL/5FU *** P<0.001 
0.001% PL vs 1% PL ns  P>0.05 
0.001% PL vs 1% PL/5FU *** P<0.001 
0.001% PL vs 2.5% PL *** P<0.001 
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* represent the degree of significance and ns indicates a non significant comparison. 
 
0.001% PL vs 2.5% PL/5FU *** P<0.001 
0.001% PL/5FU vs 0.01%PL *** P<0.001 
0.001% PL/5FU vs 0.01% PL/5FU ns  P>0.05 
0.001% PL/5FU vs 1% PL *** P<0.001 
0.001% PL/5FU vs 1% PL/5FU *** P<0.001 
0.001% PL/5FU vs 2.5% PL ns  P>0.05 
0.001% PL/5FU vs 2.5% PL/5FU ns  P>0.05 
0.01%PL vs 0.01% PL/5FU *** P<0.001 
0.01%PL vs 1% PL ns  P>0.05 
0.01%PL vs 1% PL/5FU ns  P>0.05 
0.01%PL vs 2.5% PL *** P<0.001 
0.01%PL vs 2.5% PL/5FU *** P<0.001 
0.01% PL/5FU vs 1% PL *** P<0.001 
0.01% PL/5FU vs 1% PL/5FU *   P<0.05 
0.01% PL/5FU vs 2.5% PL ns  P>0.05 
0.01% PL/5FU vs 2.5% PL/5FU ns  P>0.05 
1% PL vs 1% PL/5FU *** P<0.001 
1% PL vs 2.5% PL *** P<0.001 
1% PL vs 2.5% PL/5FU *** P<0.001 
1% PL/5FU vs 2.5% PL *   P<0.05 
1% PL/5FU vs 2.5% PL/5FU *** P<0.001 
2.5% PL vs 2.5% PL/5FU ns  P>0.05 
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APPENDIX C 
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON  
TESTS OF MIAPACA-2 FLOW CYTOMETRY DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* represent degree of significance, ns indicates a non significant comparison, M1 
indicates the sub G1 phase, M2 the G1 phase, M3 the S phase, M4 the G2/M phase, and 
M5 the poly-ploidic region. 
Control M1 vs 80 uM 5FU M1 ns  P>0.05 
Control M1 vs 2.5% PL M1 ns  P>0.05 
Control M1 vs 2.5% PL/5FU M1 **  P<0.01 
Control M2 vs 80 uM 5FU M2 *   P<0.05 
Control M2 vs 2.5% PL M2 ns  P>0.05 
Control M2 vs 2.5% PL/5FU M2 **  P<0.01 
Control M3 vs 80 uM 5FU M3 ns  P>0.05 
Control M3 vs 2.5% PL M3 ns  P>0.05 
Control M3 vs 2.5% PL/5FU M3 ns  P>0.05 
Control M4 vs 80 uM 5FU M4 ns  P>0.05 
Control M4 vs 2.5% PL M4 ns  P>0.05 
Control M4 vs 2.5% PL/5FU M4 ns  P>0.05 
Control M5 vs 80 uM 5FU M5 ns  P>0.05 
Control M5 vs 2.5% PL M5 ns  P>0.05 
Control M5 vs 2.5% PL/5FU M5 ns  P>0.05 
80 uM 5FU M1 vs 2.5% PL M1 ns  P>0.05 
80uM 5FU M1 vs 2.5% PL/5FU M1 ns  P>0.05 
80 uM 5FU M2 vs 2.5% PL M2 ns  P>0.05 
80 uM 5FU M2 vs 2.5% PL/5FU M2 ns  P>0.05 
80 uM 5FU M3 vs 2.5% PL M3 ns  P>0.05 
80 uM 5FU M3 vs 2.5% PL/5FU M3 ns  P>0.05 
80 uM 5FU M4 vs 2.5% PL M4 ns  P>0.05 
80 uM 5FU M4 vs 2.5% PL/5FU M4 ns  P>0.05 
80 uM 5FU M5 vs 2.5% PL M5 ns  P>0.05 
80 uM 5FU M5 vs 2.5% PL/5FU M5 ns  P>0.05 
2.5% PL M1 vs 2.5% PL/5FU M1 *   P<0.05 
2.5% PL M2 vs 2.5% PL/5FU M2 ns  P>0.05 
2.5% PL M3 vs PL/5FU M3 ns  P>0.05 
2.5% PL M4 vs 2.5% PL/5FU M4 ns  P>0.05 
2.5% PL M5 vs 2.5% PL/5FU M5 ns  P>0.05 
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APPENDIX D 
 
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON  
 
TESTS OF PANC-1 FLOW CYTOMETRY DATA 
 
 
 
Control M1 vs 80 uM 5FU M1 ns  P>0.05 
Control M1 vs 2.5% PL M1 ns  P>0.05 
Control M1 vs 2.5% PL/5FU M1 ns  P>0.05 
Control M2 vs 80 uM 5FU M2 ns  P>0.05 
Control M2 vs 2.5% PL M2 ns  P>0.05 
Control M2 vs 2.5% PL/5FU M2 ns  P>0.05 
Control M3 vs 80 uM 5FU M3 ns  P>0.05 
Control M3 vs 2.5% PL M3 ns  P>0.05 
Control M3 vs 2.5% PL/5FU M3 ns  P>0.05 
Control M4 vs 80 uM 5FU M4 ns  P>0.05 
Control M4 vs 2.5% PL M4 ns  P>0.05 
Control M4 vs 2.5% PL/5FU M4 ns  P>0.05 
Control M5 vs 80 uM 5FU M5 ns  P>0.05 
Control M5 vs 2.5% PL M5 ns  P>0.05 
Control M5 vs 2.5% PL/5FU M5 ns  P>0.05 
80 uM 5FU M1 vs 2.5% PL M1 ns  P>0.05 
80uM 5FU M1 vs 2.5% PL/5FU M1 ns  P>0.05 
80 uM 5FU M2 vs 2.5% PL M2 ns  P>0.05 
80 uM 5FU M2 vs 2.5% PL/5FU M2 ns  P>0.05 
80 uM 5FU M3 vs 2.5% PL M3 ns  P>0.05 
80 uM 5FU M3 vs 2.5% PL/5FU M3 ns  P>0.05 
80 uM 5FU M4 vs 2.5% PL M4 ns  P>0.05 
80 uM 5FU M4 vs 2.5% PL/5FU M4 ns  P>0.05 
80 uM 5FU M5 vs 2.5% PL M5 ns  P>0.05 
80 uM 5FU M5 vs 2.5% PL/5FU M5 ns  P>0.05 
2.5% PL M1 vs 2.5% PL/5FU M1 ns  P>0.05 
2.5% PL M2 vs 2.5% PL/5FU M2 ns  P>0.05 
2.5% PL M3 vs PL/5FU M3 ns  P>0.05 
2.5% PL M4 vs 2.5% PL/5FU M4 ns  P>0.05 
2.5% PL M5 vs 2.5% PL/5FU M5 ns  P>0.05 
 
* represent degree of significance, ns indicates a non significant comparison, M1 
indicates the sub G1 phase, M2 the G1 phase, M3 the S phase, M4 the G2/M phase, and 
M5 the poly-ploidic region. 
 
 
 62 
 
 
 
 
APPENDIX E 
 
ANNEXIN V AND PI STAINING FOR DEGREE OF APOPTOSIS 
IN PANC-1 CELLS  
 
 
 
PANC-1: Degree of Apoptosis Time Study
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Values in chart represent the percentages of cell in a particular state of viability. Courtesy 
of Malyn Asuncion of the Nathan Wall lab. 
